Conference Perspectives

Benjamin Weinberg, MD, shares the clinical implications of how data from the 2020 ASCO Virtual Scientific Program may impact in the treatment of patients with colorectal cancer and projects what the future may hold in the space.

Omid Hamid, MD, highlights key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.

Omid Hamid, MD, highlights key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.

We traveled to Kansas City, Missouri, for a State of the Science Summit™ on Hematologic Malignancies, which provided a comprehensive snapshot of the pivotal data that were presented at the 2018 ASH Annual Meeting.

We traveled to San Diego, California, for the 2018 ASH Annual Meeting, where we spoke with several experts across hematologic malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma.

We headed to San Antonio, Texas, for the San Antonio Breast Cancer Symposium, where we spoke to several principal investigators who detailed new applications of novel therapies, surgical intervention strategies, and lifestyle modifications.

The 2018 ESMO Congress brought us all the way to Munich, Germany. At this annual congress, data across various tumor types were presented, including genitourinary malignancies, breast cancer, head and neck squamous cell carcinoma, melanoma, gastrointestinal malignancies, and lung cancer.